CCM Biosciences Announces Presentation of Data on its First-In-Class AML Drug Program at ASCO 2025

CCM Biosciences Announces Presentation of Data on its First-In-Class AML Drug Program at ASCO 2025

Company’s AML drug program is focused on both newly diagnosed and relapsed/refractory FLT3-positive AML, overcoming major forms of resistance to FDA-approved FLT3 inhibitors, and outperforms other investigational inhibitors in a wide range of drug resistance models.

CCM Biosciences Announces Presentation of Data on its First-In-Class NSCLC Drug Program at ASCO 2025

Company’s NSCLC drug program is focused on overcoming both mutational and non-mutational resistance to 3rd-generation EGFR inhibitors and outperforms other investigational 4th-generation inhibitors in a wide range of drug resistance models. MOUNT LAUREL, N.J.–(BUSINESS WIRE)–CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its 4th-generation EGFR inhibitor drug program …